Cabaletta Bio, Inc. · NASDAQ:CABA

Cabaletta Bio — Investor Presentation (January 2024)

19 slides from Cabaletta Bio's investor presentation, Jan 8, 2024

1. Slide 1: Corporate Presentation January 2024

   Exhibit 99.1 Corporate Presentation JANUARY 2024 © 2024 Cabaletta Bio. All rights reserved.

2. Slide 2: Disclaimer

   Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection wi

3. Slide 3: Develop and launch the first curative targeted cellular therapies for autoimmune diseases

   Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases 3 3

4. Slide 4: Realizing the vision to transform autoimmune disease treatment

   Realizing the vision to transform autoimmune disease treatment 2H24: Initial clinical data systemic sclerosis & generalized 1H24: myasthenia Initial clinical data gravis myositis & systemic lupus Designed novel Phase 1/2 trials erythematosus to accelerate path to approval • no requirement for dose e

5. Slide 5: Pipeline targeting autoimmune diseases with high unmet need

   Pipeline targeting autoimmune diseases with high unmet need Innovative and scalable clinical strategy with potential for accelerated development path Phase 1/2 Pivotal Program Trial Preclinical Dermatomyositis Rheumatology Neurology RESET-Myositis™ Anti-synthetase syndrome Dermatology IMNM Lupus Nep

6. Slide 6: Chimeric Antigen Receptor T Cells for Autoimmunity: CABA-201

   Chimeric Antigen Receptor T Cells for Autoimmunity CABA-201 6

7. Slide 7: Academic data: Immune system reset in autoimmune patients

   Academic data: Immune system reset in autoimmune patients 1,2 Promising clinical responses in 15 patients across several autoimmune diseases with 4-1BB CD19-CAR T <7% 3-7 Rate of CRS more Months to naïve B severe than fever cell repopulation (1/15) 100% 2+ Years of SLE Objective clinical 11/15 patie

8. Slide 8: CABA-201: CD19-CAR T specifically designed for autoimmunity

   CABA-201 CABA-201: CD19-CAR T specifically designed for autoimmunity 1,2 3,4 Cabaletta’s CD19 binder with similar in vitro & in vivo activity to FMC63 (binder used in academic studies ) Clinical data reported by IASO using 5 licensed CD19 binder in oncology Fully human anti-CD19 binder Similar bindi

9. Slide 9: RESET Phase 1/2 trials advancing

   CABA-201 REstoring SElf-Tolerance (RESET™) Phase 1/2 trials advancing SLE & myositis trials currently recruiting, with a broadening portfolio to realize the potential of CABA-201 Phase 1/2 Trials Preclinical Rheum Myositis SLE SSc gMG 2024 Neuro Undiscl. > > > > Typical onset middle age Affects youn

10. Slide 10: Clinical strategy to reduce risk, maximize reach & accelerate timelines

    CABA-201 Clinical strategy to reduce risk, maximize reach & accelerate timelines Broad investigation of CABA-201 in well-defined patient populations with the same dose & similar design RESET-Myositis™ RESET-SLE™ RESET-SSc™ RESET-MG™ Lupus ASyS Skin + Organ AChR+ Nephritis Cohort Involvement gMG CABA

11. Slide 11: RESET-Myositis: Phase 1/2 study design for CABA-201

    CABA-201 RESET-Myositis™: Phase 1/2 study design for CABA-201 Currently enrolling patients with active myositis with DM, ASyS or IMNM subtypes Screening Phase 1/2 Study Design Study Objectives Open-label trial with parallel 6-subject cohorts Adults 18-65y Primary objective Safety & tolerability with

12. Slide 12: RESET-SLE: Phase 1/2 study design for CABA-201

    CABA-201 RESET-SLE™: Phase 1/2 study design for CABA-201 Currently enrolling patients with active SLE with or without renal involvement Screening Phase 1/2 Study Design Study Objectives Open-label trial with parallel 6-subject cohorts Adults 18-65y Primary objective Safety & tolerability within Clin

13. Slide 13: Evaluation metrics to assess outcomes of CAR T in autoimmunity

    Evaluation metrics to assess outcomes of CAR T in autoimmunity st For CABA-201, translational effects in 1 month may inform clinical outcomes at 3 months CAR T & Single Infusion 1 B cell levels Anti-CD19 Following treatment with autologous CD19-CAR T, 5 pts CAR T Cells with 14+ mo. of drug-free remi

14. Slide 14: Manufacturing strategy

    Manufacturing strategy Staged approach allows for efficient allocation of capital while leveraging experienced partners Early Phase: Late Phase & Commercial: Penn, CDMOs & CABA Process Scale-Up & Commercialization Data-gated, staged investment Ongoing • Penn has reliably provided timely product for

15. Slide 15: Securing & expanding our leadership in autoimmune cell therapy

    Securing & expanding our leadership in autoimmune cell therapy Rapidly advancing to address patient need Broadening potential to serve patients Advancing the RESET™ clinical trials Biologic opportunity for potential cure or paradigm-shifting treatment with the goal of delivering on our commitment to

16. Slide 16: Corporate Summary

    Corporate Summary Cabaletta Bio’

17. Slide 17: Cabaletta Bio leadership

    Cabaletta Bio leadership LEADERSHIP TEAM Steven Nichtberger, M.D. Samik Basu, M.D. Gwendolyn Binder, Ph.D. David J. Chang, M.D., M.P.H., FACR Arun Das, M.D. President, CEO & Chairman Chief Scientific Officer President, Science & Technology Chief Medical Officer Chief Business Officer Michael Gerard

18. Slide 18: Realizing the vision to transform autoimmune disease treatment

    Realizing the vision to transform autoimmune disease treatment 2H24: Initial clinical data systemic sclerosis & generalized 1H24: myasthenia Initial clinical data Well-positioned to continue gravis myositis & executing on our vision systemic lupus Designed novel Phase 1/2 trials erythematosus to acc

19. Slide 19: © 2024 Cabaletta Bio. All rights reserved.

    Corporate Presentation JANUARY 2024 © 2024 Cabaletta Bio. All rights reserved.

Cabaletta Bio — Investor Presentation (January 2024) on 6ix